Sources
What the tools rely on
- US products: the FDA-approved labeling (prescribing information and patient information, or the Drug Facts label for over-the-counter products), from DailyMed, the U.S. National Library of Medicine's label database.
- UK products: the Summary of Product Characteristics (SmPC), from the electronic medicines compendium (EMC), and for a ring note the UK patient leaflet, NuvaRing: Patient Information Leaflet (PIL).
- The US Depo interval: also the CDC's U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (MMWR Recomm Rep 2024;73(No. RR-3)).
- UK Depo-Provera injected into a muscle: UK guidance for clinicians, FSRH CEU Guidance: Progestogen-only Injectable Contraception, is linked only to explain why the tool gives no single date. Its text is not reproduced here.
The site quotes the product labels briefly and links to every document. It does not republish any of them. The sources were last retrieved on 31 October 2026.
Product schedules
Each row is a product the tools use, with a link to its label document, the version, and the dates it was retrieved, verified and is due for review.
| Product | Country | Document | Version | Retrieved | Verified | Review by |
|---|---|---|---|---|---|---|
| Depo-Provera (150 mg injection into a muscle) | CountryUK | DocumentUK SmPC (Pfizer Limited), via the electronic medicines compendium (emc) | VersionSmPC section 10 'Date of revision of the text': 09/2025; 'Last updated on emc: 29 Sep 2025' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Sayana Press (104 mg injection under the skin) | CountryUK | DocumentUK SmPC (Pfizer Limited), via the electronic medicines compendium (emc) | VersionSmPC section 10 'Date of revision of the text': 09/2025; 'Last updated on emc: 16 Sep 2025' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Depo-Provera CI (150 mg injection into a muscle) | CountryUS | DocumentFDA-approved label (Pfizer), via DailyMed | VersionDailyMed setid 199cf13e-0859-4a73-9b45-e700d0cd1049, SPL version 29, effective 2026-08-25 (published on DailyMed Aug 28, 2026) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| depo-subQ provera 104 (injection under the skin) | CountryUS | DocumentFDA-approved label (Pfizer), via DailyMed | VersionDailyMed setid 390087a6-f3c3-4f0b-a930-79acf412f153, SPL version 21, effective 2025-12-18 (published on DailyMed Dec 19, 2025) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Evra (weekly patch) | CountryUK | DocumentUK SmPC (Gedeon Richter (UK) Ltd), via the electronic medicines compendium (emc) | VersionSmPC section 10 'Date of revision of the text': 03/05/2023; 'Last updated on emc: 15 May 2023' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Twirla (weekly patch) | CountryUS | DocumentFDA-approved label (Agile Therapeutics), via DailyMed | VersionDailyMed setid bcaf8db0-1750-425d-b008-255b5e7a9cc6, SPL version 9, effective 2026-06-30 (published on DailyMed Jul 02, 2026); label 'Revised: 06/2026' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Xulane (weekly patch) | CountryUS | DocumentFDA-approved label (Mylan), via DailyMed | VersionDailyMed setid f7848550-086a-43d8-8ae5-047f4b9e4382, SPL version 17, effective 2022-03-04 (published on DailyMed Jun 15, 2026); label 'Revised: 3/2022' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Zafemy (weekly patch) | CountryUS | DocumentFDA-approved label (Amneal), via DailyMed | VersionDailyMed setid 5ee34c07-65af-42b8-a98f-e299ff90a8a1, SPL version 7, effective 2022-04-30 (published on DailyMed Apr 28, 2025) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| NuvaRing (monthly ring) | CountryUK | DocumentUK SmPC (Organon Pharma (UK) Limited), via the electronic medicines compendium (emc) | VersionSmPC section 10 'Date of revision of the text': 27 May 2026; 'Last updated on emc: 15 Jun 2026' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| EluRyng (monthly ring) | CountryUS | DocumentFDA-approved label (Amneal), via DailyMed | VersionDailyMed setid c6c8512d-b258-4be5-8c2f-0f1893f198b9, SPL version 21, effective 2025-01-15 (published on DailyMed Jan 30, 2025) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Generic etonogestrel/ethinyl estradiol vaginal ring (monthly, Teva) | CountryUS | DocumentFDA-approved label (Teva), via DailyMed | VersionDailyMed setid a8cc104a-d522-49ad-af54-2f312b829b61, SPL version 5, effective 2022-09-30 (published on DailyMed Sep 10, 2025) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| NuvaRing (monthly ring) | CountryUS | DocumentFDA-approved label (Organon), via DailyMed | VersionDailyMed setid 55eb60e3-6f4d-40a3-8ee6-e7fd2d0c7d97, SPL version 10, effective 2025-11-14 (published on DailyMed Nov 21, 2025); label 'Revised: 12/2024' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Cerazette (progestin-only, 28 tablets, no break) | CountryUK | DocumentUK SmPC (Organon Pharma (UK) Limited), via the electronic medicines compendium (emc) | VersionSmPC section 10 'Date of revision of the text': 23 December 2024; 'Last updated on emc: 08 Jan 2025' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Microgynon 30 (21 tablets + 7-day break) | CountryUK | DocumentUK SmPC (Bayer plc), via the electronic medicines compendium (emc) | VersionSmPC section 10 'Date of revision of the text': 13 February 2023; 'Last updated on emc: 23 Feb 2023' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Amethyst (continuous, no break) | CountryUS | DocumentFDA-approved label (Teva), via DailyMed | VersionDailyMed setid 99073fe0-eac8-44dd-abe6-623fa67d9e79, SPL version 3, effective 2022-01-31 (published on DailyMed Sep 08, 2025) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Camrese (91-day pack: 84 + 7) | CountryUS | DocumentFDA-approved label (Teva), via DailyMed | VersionDailyMed setid 0e198d28-4986-4b93-833f-17c7ed4ce13e, SPL version 19, effective 2024-10-31 (published on DailyMed Sep 21, 2026); label 'Revised: 10/2024' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Heather (progestin-only, 28 tablets, no break) | CountryUS | DocumentFDA-approved label (Glenmark), via DailyMed | VersionDailyMed setid 35b5ddb5-1729-4588-b2a2-ead56d78b6f9, SPL version 12, effective 2026-01-23 (published on DailyMed Jan 26, 2026) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Lo Loestrin Fe (24 + 2 + 2) | CountryUS | DocumentFDA-approved label (Allergan/AbbVie), via DailyMed | VersionDailyMed setid c33072cf-625d-4b4a-981e-ec049c5d78aa, SPL version 25, effective 2025-03-07 (published on DailyMed Jun 26, 2026) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Opill (progestin-only, 28 tablets, no break) | CountryUS | DocumentFDA-approved OTC label (Perrigo), via DailyMed | VersionDailyMed setid 69dfa2ac-6a7e-4587-929c-9acabd97973b, SPL version 4, effective 2025-01-27 (published on DailyMed Jan 29, 2025) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Slynd (progestin-only, 24 active + 4 inert) | CountryUS | DocumentFDA-approved label (Exeltis), via DailyMed | VersionDailyMed setid db32bc55-f295-4d87-9dbb-0a2f45573dcf, SPL version 9, effective 2026-08-27 (published on DailyMed Aug 31, 2026); label 'Revised: 06/2025' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Sprintec (21 active + 7 inactive) | CountryUS | DocumentFDA-approved label (Teva), via DailyMed | VersionDailyMed setid d9252820-131a-4870-8b11-945d1bfd5659, SPL version 13, effective 2024-12-19 (published on DailyMed Jan 30, 2025) | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
| Taytulla (24 active + 4 inactive capsules) | CountryUS | DocumentFDA-approved label (Allergan/AbbVie), via DailyMed | VersionDailyMed setid 2fa8e8dc-f7b0-429a-b554-0e3c4291c92c, SPL version 16, effective 2024-10-25 (published on DailyMed May 11, 2026); label 'Revised: 10/2024' | Retrieved31 October 2026 | Verified31 October 2026 | Review by30 April 2027 |
How dates are counted
- For a calculated schedule, the date you enter is the first day, and every other date is that day plus a whole number of days: from the label or, in the pack tool's format mode, from the pack size you enter. A date your clinic gave you, entered in the Depo tool's clinic-date mode, is kept exactly as entered.
- Dates are calendar dates with no time of day, so month ends, leap days, year ends and clock changes don't move them.
- "Today" is your device's date. It is used only to count the days since a date, to mark dates as passed, and to check what you enter. For review-by dates, the later of your device's date and our server's date is used.
- Dates are written with the weekday, for example Saturday, 13 February 2027.
- A time-of-day instruction, such as taking a ring out at about the same time, is shown as text only. The tools don't use the time of day, except for the optional calendar alert, which is set for the morning of each date.
Review and re-checks
Every product record has a review-by date, shown in the table. Once it passes, the tool withholds that product's schedule until the record has been re-checked, and the product's status line links its official label, under "Official product information". For each product, the version of its main label document (the US label or the UK SmPC) is recorded in the evidence ledger, and a script compares it with the current version on DailyMed or the EMC. The UK patient leaflet used for the ring note is not part of this check. The last check, on 31 October 2026, found no changes.
Your leaflet and your clinician come first
If the leaflet in your pack or your clinician gives a different date or instruction, follow them. Labels are updated, and your situation may not be routine.